Jubilant says the FDA has cleared its Canada plant

It is one down and one to go for Indian drugmaker Jubilant Life Sciences when it comes to satisfying the FDA over the operations of its North American manufacturing facilities. The company says the FDA has given it a clean bill of health on a facility in Montreal, Canada, that was issued a warning letter in February 2013. The drugmaker has another facility in Spokane, WA, where the FDA still has concerns.

The FDA has yet to publicly post a close-out letter indicating its satisfaction, but the company felt comfortable enough to issue a statement Friday that all is well with the Canadian plant where it makes sterile injectable drugs. It says: "Jubilant Life Sciences has received a communication from the US Food and Drug Administration (FDA), classifying its pharmaceutical manufacturing facility at Montreal, Canada, as 'Acceptable.' This resolves all issues raised by the FDA on the facility in February 2013 and subsequent communications."

Among the problems the FDA cited in its 2012 visit to the Montreal plant was the fact that it released drug batches that had failed to meet 100% of its visual inspections and that it didn't get to the root cause of why batches failed. An inspector was also concerned about water running on the floor of the equipment washroom that was tracked into the pharmaceutical corridor leading to the sterile production hallway, a production line, and the vial-filling area. But Friday the drugmaker said that the FDA signed off on the plant after a re-inspection in September.

The statement made no reference to Jubilant's Spokane facility, which received a warning letter in November. Among other problems, the FDA noted in that inspection that the plant had not put together a written plan, with Quality Control oversight, of how sterile manufacturing might be affected by a major remodeling that included replacing windows, resurfacing the floors and painting ceilings. The inspectors also noted it had not gotten to the root cause of unexplained increased levels of some impurities which led Jubilant to recall some products.

Still, Jubilant getting the Montreal plant back on track with the FDA is a piece of good news for the Indian drug industry, which has had its fair share of problems as of late. Since May of last year, the FDA has banned two Ranbaxy Laboratories plants and two Wockhardt plants from exporting to the U.S. Their problems were repeatedly hashed over in world media reports during a recent trip by FDA Commissioner Margaret Hamburg to India, where quality manufacturing was at the top of of her discussion list.

- here's the release

Related Articles:
FDA spanks a second Jubilant HollisterStier plant
Jubilant joins list of Indian drugmakers cited by the FDA
FDA picks apart processes at Jubilant HollisterStier plant
Hamburg says FDA's focus on India reflects its place in the global supply chain
FDA warning letter lays out issues at banned Wockhardt plants
FDA extends Ranbaxy consent decree to Mohali plant

Suggested Articles

McCallum was hit with a warning letter from the FDA for testing issues with its products and failing to keep appropriate records.

The FDA made public a voluntary recall of sterile injectables made by Coastal Meds of Mississippi, after visible particles were found in some vials.

It’s been a strange road for BMS' Opdivo-Yervoy combo in first-line kidney cancer, but the New Jersey drugmaker finally has a go-ahead.